Available online at *www.ujpronline.com*
Universal Journal of Pharmaceutical Research
An International Peer Reviewed Journal
ISSN: 2831-5235 (Print); 2456-8058 (Electronic)

REVIEW ARTICLE

THE ROLE OF AFRICAN UNIVERSITIES AND RESEARCH INSTITUTIONS IN ADVANCING SICKLE CELL DISEASE INNOVATION: A PERSPECTIVE

Emmanuel Ifeanyi Obeagu[*1,2], Priya Homa Chukwu[3]

[1]*Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.*
[2]*Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.*
[3]*Department of Haematology and Blood Transfusion Science, Rivers State University, Port Harcourt, Rivers State, Nigeria.*

Article Info:

Article History:
Received: 6 December 2025
Reviewed: 10 January 2026
Accepted: 13 Februray 2025
Published: 15 March 2026

Cite this article:
Obeagu EI, Chukwu PH. The role of African universities and research institutions in advancing sickle cell disease innovation: A perspective. Universal Journal of Pharmaceutical Research 2026; 11(1): 74-79.
http://doi.org/10.22270/ujpr.v11i1.1493

***Address for Correspondence:**
Dr. Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe; Tel: +263-77802 5658
E-mail: *emmanuelobeagu@yahoo.com*

Abstract

Sickle Cell Disease (SCD) continues to be one of the most common genetic illnesses in Africa, greatly affecting morbidity and mortality throughout the continent. African universities and research institutions have become crucial contributors to driving innovation to address this challenge through targeted research, skill development, and advocacy in policy. Their targeted initiatives are crucial in tackling the distinct genetic, environmental, and socio-economic factors affecting SCD in African communities. These organizations have significantly advanced the knowledge of the molecular genetics of SCD, performed epidemiological research, and conducted clinical trials suited to local environments. Moreover, they are vital in educating healthcare practitioners and researchers, which enhances the continent's ability to deliver efficient care and create innovative treatment methods. Collaborative research networks and specialized centers enhance innovation, promoting the application of scientific findings into tangible solutions like newborn screening and point-of-care diagnostics.

Keywords: African Universities, genetic disorders, public health, research innovation, sickle cell disease.

INTRODUCTION

Sickle Cell Disease (SCD) is an inherited blood disorder resulting from a mutation in the β-globin gene, which leads to the formation of faulty hemoglobin S. This defect causes red blood cells to take on a sickle or crescent shape, leading to chronic hemolytic anemia, repeated vaso-occlusive crises, and damage to multiple organs. SCD primarily impacts individuals of African descent, with the greatest prevalence and disease burden found in sub-Saharan Africa. Although SCD has been recognized as a genetic disorder for more than a hundred years, it still presents considerable clinical and public health issues in the region, mainly because of insufficient healthcare resources and infrastructural limitations[1,2]. Africa carries the majority of the global SCD burden, representing almost 75% of babies affected each year. Nations like Nigeria, Ghana, the Democratic Republic of Congo, and Tanzania exhibit some of the highest rates of SCD prevalence globally. The significant rates of illness and death, especially among children under five, highlight the pressing requirement for effective management strategies and innovations suited to the African context. Nonetheless, the distinct socio-economic, cultural, and environmental factors affecting disease manifestation and treatment response in African populations necessitate research rooted in local contexts[3,4].

Within this framework, African universities and research entities play a crucial role in promoting SCD innovation through the creation of new knowledge, the design of innovative interventions, and the preparation of proficient healthcare practitioners and researchers. These institutions function as centers for both fundamental and practical research, aiding in connecting global scientific progress with its application in African healthcare systems. Their responsibilities go beyond research to shaping national health policies and involving communities impacted by SCD[5,6]. A significant contribution of African academic institutions has been clarifying the genetic and molecular framework of SCD among various African populations. Grasping the intricate genotype-phenotype connections and the influence of genetic modifiers has opened the door for tailored treatment strategies. African researchers have made notable contributions to

epidemiological studies, detailing disease prevalence and natural history, which aids in screening programs and the distribution of resources[7,8]. Additionally, African universities have led clinical trials assessing the effectiveness and safety of treatments like hydroxylurea and blood transfusions, which are frequently underrepresented in worldwide research initiatives. These clinical efforts not only enhance evidence based medicine but also tackle practical challenges related to drug accessibility, expense, and compliance in resource-constrained environments. Training programs available at these institutions guarantee a continuous supply of healthcare professionals and researchers who grasp the intricacies of SCD in their communities[9,10].

Burden of sickle cell disease in Africa

SCD poses a significant health challenge in Africa, where the highest global rates are found. Around 300,000 children are born with SCD each year globally, with about 75% of these births taking place in sub-Saharan Africa. Nations like Nigeria, Democratic Republic of Congo, Ghana, Tanzania, and Uganda show notably elevated carrier rates of the sickle cell trait (HbAS), frequently surpassing 20% in certain areas, leading to a significant occurrence of SCD (HbSS) births. The significant frequency of this trait is strongly associated with the protective benefit that the sickle cell trait offers against severe malaria, which is prevalent in numerous regions of Africa[11,12]. The impact of SCD in Africa is evident not just in its frequency but also in the related rates of illness and death. SCD plays a major role in childhood death, with estimates indicating that as many as 50–90% of impacted children in sub-Saharan Africa die before reaching five years old, mainly from complications like infections, severe anemia, and stroke that frequently remain untreated or inadequately managed. In contrast to high-income nations, where newborn screening, preventive treatments, and thorough care have significantly enhanced survival rates, numerous African countries do not have structured screening initiatives and struggle with deficits in vital medications and healthcare staff[13].

Apart from mortality, SCD brings persistent health issues, such as repeated vaso-occlusive episodes, ongoing pain, organ deterioration, and a heightened risk of infections. These issues frequently result in increased hospital visits and decreased quality of life. The socio-economic effects are significant, as impacted individuals and families encounter direct healthcare expenses and indirect costs due to decreased productivity and disruptions in education. In areas where healthcare systems are underdeveloped and social support is minimal, the financial strain on families and communities is significant[14]. The diagnosis and treatment of SCD in Africa are hindered by a general lack of awareness, stigma, and limited access to healthcare, particularly in rural regions. Numerous patients stay undiagnosed until significant complications occur, underscoring the necessity for enhanced newborn screening and early intervention initiatives. Additionally, cultural beliefs and traditional medical practices can occasionally impede or postpone the adoption of biomedical care, highlighting the necessity of culturally aware public health efforts[15].

Role of African Universities in sickle cell disease research

African universities play a crucial role in advancing SCD research by generating context-specific knowledge and developing innovations that address the unique challenges of the disease on the continent. As centers of academic excellence, these institutions drive research efforts spanning molecular biology, epidemiology, clinical trials, and public health interventions, thereby contributing to a comprehensive understanding of SCD within African populations[16].

Genetic and molecular research

One of the most significant contributions of African universities is in the field of genetics and molecular biology. Universities such as the University of Ibadan in Nigeria, Makerere University in Uganda, and the University of Cape Town in South Africa have undertaken extensive studies to explore the genetic diversity of SCD patients across different regions. These investigations have focused on identifying genetic modifiers, such as fetal hemoglobin levels and co-inheritance of alpha-thalassemia, that influence disease severity and clinical outcomes. By unraveling the complex genotype-phenotype relationships unique to African populations, these studies provide vital insights for personalized medicine and the development of targeted therapies[17].

Epidemiological and clinical research

African universities also conduct critical epidemiological research to map the prevalence, distribution, and natural history of SCD. These studies inform public health strategies, including the design of newborn screening programs and community-based interventions. Additionally, clinical research led by these institutions evaluates treatment modalities such as hydroxyurea therapy, transfusion protocols, and pain management strategies, assessing their safety, efficacy, and feasibility in resource-constrained settings. This localized evidence is invaluable for developing context-appropriate clinical guidelines that improve patient outcomes[18].

Capacity building and training

Beyond research, African universities are instrumental in building human capacity by training healthcare professionals, genetic counselors, and researchers who specialize in SCD. Postgraduate programs, workshops, and continuous professional development initiatives help cultivate a skilled workforce equipped to manage SCD clinically and advance scientific research. Furthermore, many universities foster collaborations with international partners, enhancing knowledge exchange and providing access to cutting-edge technologies and methodologies[19].

Research networks and collaboration

African universities are increasingly involved in regional and international research networks focused on SCD. These collaborations facilitate resource sharing, standardization of research protocols, and large-scale multicenter studies that enhance the generalizability of findings. Networks such as the African Sickle Cell Disease Research Network

(AfriSCDNet) exemplify how coordinated efforts can accelerate innovation, increase funding opportunities, and amplify the impact of research on policy and practice[20].

Community engagement and advocacy

Recognizing the importance of community involvement, many universities engage with patient groups and local communities to raise awareness about SCD, reduce stigma, and improve healthcare access. Academic institutions often serve as bridges between research and society, ensuring that findings translate into culturally appropriate education programs and advocacy efforts that influence public health policy[21].

Research institutions driving innovation

In addition to universities, specialized research institutions across Africa play a pivotal role in advancing innovation in SCD through focused research, translational studies, and the development of novel diagnostic and therapeutic tools. These institutions often operate as dedicated centers of excellence that complement university efforts by concentrating resources, expertise, and infrastructure to address the multifaceted challenges posed by SCD[22,23].

Centers of excellence and dedicated research networks

Several African countries have established centers of excellence specifically focused on hemoglobinopathies, including SCD. For instance, the Sickle Cell Foundation Nigeria and the Hematology and Blood Transfusion Research Group at the University of KwaZulu-Natal (South Africa) are notable for their contributions to both basic and clinical research. These centers provide a platform for multidisciplinary collaboration involving hematologists, geneticists, epidemiologists, and public health specialists, enabling a comprehensive approach to innovation in SCD[24]. Moreover, regional and continental research networks, such as the African Sickle Cell Disease Research Network (AfriSCDNet), have emerged as critical drivers of collaborative innovation. These networks foster partnerships between universities, hospitals, and research institutions, facilitating large-scale clinical trials, genomic studies, and health systems research that are tailored to the African context. They also promote capacity building by training emerging researchers and standardizing research methodologies[25].

Translational research and technology development

African research institutions are increasingly engaged in translational research that bridges laboratory discoveries with clinical applications. This includes the development of affordable point-of-care diagnostic tools that enable early detection of SCD and related complications in resource-limited settings. For example, novel rapid testing kits and portable devices developed through collaborative projects have enhanced newborn screening capabilities in rural and underserved areas[26]. In addition to diagnostics, these institutions contribute to therapeutic innovation by evaluating existing and emerging treatments within African populations. Clinical trials conducted in African research centers assess the safety and efficacy of hydroxyurea, gene therapy prospects, and other pharmacological interventions. Such research is crucial because drug responses and side effect profiles may differ due to genetic and environmental factors unique to African patients[27,28].

Public health innovation and community-based interventions

Research institutions also drive innovation in public health strategies aimed at improving SCD management and reducing disease burden. They design and implement community-based programs that enhance patient education, adherence to treatment, and psychosocial support. Innovative approaches leveraging mobile health technologies and community health workers have been piloted and scaled in several countries, demonstrating improved clinical outcomes and quality of life for patients[28].

Policy engagement and knowledge translation

Beyond research, African institutions play a vital role in translating evidence into policy and practice. By generating robust data and policy briefs, they support governments in formulating national SCD programs that include newborn screening, patient registries, and access to essential medicines. Their advocacy efforts, often in partnership with patient organizations, have been instrumental in raising the profile of SCD on national health agendas and securing funding for research and care[27].

Policy influence and advocacy

African universities and research institutions play a vital role in shaping policies and advocating for improved care and research funding for Sickle Cell Disease (SCD). Through evidence generation, expert consultation, and collaboration with government agencies and civil society, these institutions help translate scientific findings into actionable policies that address the pressing needs of individuals affected by SCD across the continent.

Evidence-based policy development

By conducting rigorous research on the epidemiology, clinical management, and socio-economic impact of SCD, African academic and research institutions provide policymakers with robust data needed for informed decision-making. For example, studies highlighting the high mortality rates in children with undiagnosed SCD have been instrumental in persuading governments to implement or expand newborn screening programs. Similarly, research on the cost-effectiveness of treatments like hydroxyurea supports their inclusion in national essential medicines lists and insurance schemes[27].

Collaboration with governments and health ministries

Universities and research centers often serve as trusted partners to health ministries and regulatory bodies in drafting national SCD policies, guidelines, and strategic plans. Their involvement ensures that policies are scientifically sound, contextually appropriate, and feasible for implementation within existing health systems. In countries such as Nigeria, Ghana, and Tanzania, research institutions have been central to the development of national SCD control programs that incorporate screening, comprehensive care, and community education[29].

Advocacy and awareness raising

Beyond policy formulation, African institutions engage in advocacy to raise awareness about SCD among policymakers, healthcare providers, and the general public. They organize conferences, workshops, and public campaigns that highlight the burden of SCD and the potential of research-driven innovations to improve outcomes. Partnerships with patient organizations and media outlets amplify these efforts, helping reduce stigma and mobilize political will and funding[29].

Capacity building for policy implementation

Recognizing that policy success depends on effective implementation, universities contribute by training healthcare workers, policymakers, and community leaders in SCD management and advocacy. This capacity building fosters local ownership and sustainability of programs, ensuring that policies translate into tangible improvements in diagnosis, treatment, and patient support[30].

Challenges and limitations

Despite significant progress made by African universities and research institutions in advancing SCD innovation, numerous challenges continue to hinder the full realization of their potential. These limitations span financial, infrastructural, human resource, and systemic domains, which collectively constrain research capacity, clinical translation, and sustainable impact[31].

Funding constraints

One of the foremost challenges is inadequate funding for SCD research and healthcare programs. Many African universities and institutions rely heavily on external grants from international agencies and philanthropic organizations, which are often competitive and time-limited. Insufficient domestic investment restricts the ability to establish and maintain state-of-the-art laboratories, recruit and retain skilled personnel, and conduct large-scale, long-term studies. The fragmented funding landscape also limits the capacity to implement comprehensive newborn screening and treatment programs at a national level[32].

Infrastructural limitations

Research infrastructure remains underdeveloped in many African institutions. There is a lack of advanced molecular and genomic laboratories, limited access to modern diagnostic equipment, and challenges with data management systems. These gaps impede cutting-edge research, including genomics, proteomics, and bioinformatics studies essential for understanding SCD complexity in African populations. Moreover, inconsistent power supply, internet connectivity, and laboratory consumables availability further disrupt research activities[33,34].

Human resource challenges

Brain drain and shortage of specialized expertise significantly affect SCD research and clinical care. Many trained researchers and clinicians migrate to high-income countries seeking better opportunities, leaving gaps in mentorship, leadership, and service provision. Additionally, there is often a limited number of healthcare workers trained specifically in hematology and genetic counseling. This shortage compromises not only research capacity but also the quality of patient care and community education[35,36].

Regulatory and ethical barriers

Clinical trials and research involving genetic data require robust regulatory oversight to ensure ethical standards and participant safety. However, many African countries face challenges in regulatory harmonization, leading to delays in trial approvals and difficulties in cross-border collaborations. Informed consent processes and community engagement can be complex due to varying literacy levels, cultural perceptions, and mistrust, necessitating tailored approaches that may slow research progress[37].

Data deficiencies and fragmentation

Comprehensive data collection and management are crucial for epidemiological studies, monitoring treatment outcomes, and informing policy. However, many African countries lack centralized SCD registries and electronic health record systems. Data fragmentation across different institutions and regions hampers the ability to conduct large-scale, longitudinal research and to track patients effectively. This limits evidence-based decision-making and the ability to evaluate intervention impact accurately[19].

Socio-cultural and economic barriers

Social stigma, misconceptions about SCD, and economic hardships faced by patients and families impede healthcare access and adherence to treatment protocols. Research efforts sometimes struggle to translate findings into practice due to these socio-cultural factors, underscoring the need for culturally sensitive community engagement and education programs. Economic barriers, including out-of-pocket healthcare costs, further limit the uptake of innovative therapies and diagnostic services[38,39].

Opportunities for overcoming challenges

Addressing these limitations requires multifaceted strategies, including increased governmental commitment and funding, infrastructure development, capacity building, and strengthening regulatory frame-works. International partnerships, technology transfer, and regional collaboration can help bridge gaps in expertise and resources. Emphasizing community involvement and culturally appropriate interventions will also enhance the acceptance and effectiveness of SCD innovations[40].

CONCLUSIONS

African universities and research institutions are at the forefront of advancing innovation in Sickle Cell Disease, addressing one of the continent's most pressing genetic health challenges. Through multidisciplinary research, capacity building, and policy advocacy, these institutions have generated critical knowledge that informs diagnosis, treatment, and public health strategies tailored to African contexts. Their efforts in unraveling the genetic complexities of SCD, conducting clinical trials, and developing point-of-care technologies have significantly contributed to improving patient outcomes and reducing disease burden. However, persistent challenges such as limited funding, infrastructural deficits, human resource shortages, and regulatory hurdles continue to impede the full potential of SCD research and innovation.

Overcoming these barriers requires increased investment, enhanced regional and international collaborations, and the integration of emerging technologies. Equally important is the strengthening of policy frameworks and community engagement to ensure that scientific advancements translate into accessible and equitable care.

ACKNOWLEDGEMENTS

The authors express their gratitude to Africa University, Mutare, Zimbabwe to provide necessary facilities for this work.

AUTHOR'S CONTRIBUTION

Obeagu EI: conceived the idea, writing the manuscript, critical review. **Chukwu PH:** literature survey, formal analysis, data processing. Final manuscript was checked and approved by both authors.

DATA AVAILABILITY

The empirical data used to support the study's conclusions are available upon request from the corresponding author.

CONFLICT OF INTEREST

Regarding this project, there are no conflicts of interest.

REFERENCES

1. Elendu C, Amaechi DC, Alakwe-Ojimba CE, *et al*. Understanding sickle cell disease: Causes, symptoms, and treatment options. Medicine (Baltimore) 2023;102(38): e35237. *https://doi.org/10.1097/MD.0000000000035237*
2. Inusa BPD, Hsu LL, Kohli N, *et al*. Sickle cell disease-genetics, pathophysiology, clinical presentation and treatment. Int J Neonat Screen 2019;5(2):20. *https://doi.org/10.3390/ijns5020020*
3. Adigwe OP, Onoja SO, Onavbavba G. A Critical review of sickle cell disease burden and challenges in Sub-Saharan Africa. J Blood Med 2023; 14:367-376. *https://doi.org/10.2147/JBM.S406196*
4. Nnodu OE, Okeke CO, Isa HA. Newborn screening initiatives for sickle cell disease in Africa. Hematology Am Soc Hematol Educ Program 2024; 2024(1):227-233. *https://doi.org/10.1182/hematology.2024000548*
5. Van Niekerk L, Mathanga DP, Juban N, *et al*. Universities as catalysts of social innovation in health systems in low-and middle-income countries: A multi-country case study. Infect Dis Poverty 2020;9(1):90. *https://doi.org/10.1186/s40249-020-00684-5*
6. Abubakar I, Dalglish SL, Angell B, *et al*. The Lancet Nigeria Commission: Investing in health and the future of the nation. Lancet 2022;399(10330):1155-1200. *https://doi.org/10.1016/S0140-6736(21)02488-0*
7. Musuka HW, Iradukunda PG, Mano O, *et al*. Evolving landscape of sickle cell anemia management in Africa: A critical review. Trop Med Infect Dis 2024;9(12):292. *https://doi.org/10.3390/tropicalmed9120292*
8. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annu Rev Genomics Hum Genet 2018; 19:113-147. *https://doi.org/10.1146/annurev-genom-083117-021320*
9. McGann PT, Hernandez AG, Ware RE. Sickle cell anemia in sub-Saharan Africa: Advancing the clinical paradigm through partnerships and research. Blood 2017; 129(2):155-161. *https://doi.org/10.1182/blood-2016-09-702324*
10. Power-Hays A, Tomlinson GA, Tshilolo L *et al*. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial. Am J Hematol 2024;99(4):625-632.. *https://doi.org/10.1002/ajh.27244*
11. Williams TN. Sickle cell disease in Sub-Saharan Africa. Hematol Oncol Clin North Am 2016;30(2):343-58. *https://doi.org/10.1016/j.hoc.2015.11.005*
12. Mano RM, Kuona P, Misihairabgwi JM. Determination of birth prevalence of sickle cell disease using point of care test Hemotype SC™ at Rundu Hospital, Namibia. BMC Pediatr 2024;24(1):323.*https://doi.org/10.1186/s12887-024-04805-z*
13. Grosse SD, Odame I, Atrash HK, *et al*. Sickle cell disease in Africa: A neglected cause of early childhood mortality. Am J Prev Med 2011;41(6Suppl4):S398-405. *https://doi.org/10.1016/j.amepre.2011.09.013*
14. Obeagu EI, Ezeala CC.Disrupted arginine–nitric oxide signaling in sickle cell disease: Molecular mechanisms, pathophysiological consequences and emerging Therapeutic Targets. Universal J Pharm Res 2025; 10(4): 55-61. *http://doi.org/10.22270/ujpr.v10i4.1394*
15. Saidu Y, Masong MC, Francoise N, Ngenge BM, Ndansi E, Foma MK. Sickle cell disease in Cameroon: Taking out the "neglect" and highlighting key opportunities for sustainable control. PLOS Glob Public Health 2024;4(10): e0003668. *https://doi.org/10.1371/journal.pgph.0003668*
16. Minja IK, Nkya S, Bukini D, *et al*. Strengthening global partnerships for sustainable sickle cell disease care: Insights from Sickle in Africa at the 77th United Nations General Assembly and the US-Africa Leaders' Summit. BMJ Glob Health 2025;10(3): e017154. *https://doi.org/10.1136/bmjgh-2024-017154*
17. Nembaware V. African genomic medicine training initiative; Mulder N. The African Genomic Medicine Training Initiative (AGMT): Showcasing a community and framework driven genomic medicine training for nurses in Africa. Front Genet 2019;10:1209. *https://doi.org/10.3389/fgene.2019.01209*
18. Therrell BL Jr, Lloyd-Puryear MA, Ohene-Frempong K, *et al*. Empowering newborn screening programs in African countries through establishment of an international collaborative effort. J Community Genet 2020;11(3):253-268. *https://doi.org/10.1007/s12687-020-00463-7*
19. Kuona P, Kandawasvika GQ, Chunda-Liyoka C, *et al*. Sickle hemoglobinopathy research in Zimbabwe and Zambia: setting up an international sickle cell disease registry. Front Med (Lausanne) 2025;12:1484763. *https://doi.org/10.3389/fmed.2025.1484763*
20. Nembaware V, Mazandu GK, Hotchkiss J, *et al*. The sickle cell disease ontology: Enabling collaborative research and co-designing of new planetary health applications. OMICS. 2020;24(10):559-567. *https://doi.org/10.1089/omi.2020.0153*
21. Hegemann L, Narasimhan V, Marfo K, *et al*. Bridging the access gap for comprehensive sickle cell disease management across Sub-Saharan Africa: Learnings for other global health interventions? Ann Glob Health 2023; 89(1):76. *https://doi.org/10.5334/aogh.4132*
22. Obeagu EI. Eosinophils in sickle cell anemia: Emerging molecular mechanisms and clinical implications. Universal J Pharm Res 2025; 10(2): 63-69. *http://doi.org/10.22270/ujpr.v10i2.1316*
23. Boma PM, Ngoy SKK, Panda JM, Bonnechère B. Empowering sickle cell disease care: The rise of Techno Rehab Lab in Sub-Saharan Africa for enhanced patient's perspectives. Front Rehabil Sci 2024; 5:1388855. *https://doi.org/10.3389/fresc.2024.1388855*
24. Morrice J, Mupfururirwa W, Chianumba RI. Sickle cell disease in Africa: Sickle in Africa Registry in Ghana, Nigeria and Tanzania. E J Haem 2025;6(3):e70044. *https://doi.org/10.1002/jha2.70044*
25. Tluway F, Makani J. Sickle cell disease in Africa: An overview of the integrated approach to health, research, education and advocacy in Tanzania 2004-2016. Br J Haematol 2017;177(6):919-929. *https://doi.org/10.1111/bjh.14594*
26. Alapan Y, Fraiwan A, Kucukal E, *et al*. Emerging point-of-care technologies for sickle cell disease screening and monitoring. Expert Rev Med Devices 2016;13(12):1073-1093. *https://doi.org/10.1080/17434440.2016.125403*

27. Obeagu EI, Adias TC, Obeagu GU. Advancing life: innovative approaches to enhance survival in sickle cell anemia patients. Ann Med Surg (Lond) 2024;86(10):6021-6036. *https://doi.org/10.1097/MS9.0000000000002534*
28. McGann PT, Williams TN, Olupot-Olupot P, *et al*. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. Am J Hematol 2018;93(4):537-545. *https://doi.org/10.1002/ajh.25034*
29. Ajisegiri WS, Abimbola S, Tesema AG, *et al*. Aligning policymaking in decentralized health systems: Evaluation of strategies to prevent and control non-communicable diseases in Nigeria. PLOS Glob Public Health 2021;1(11):e0000050. *https://doi.org/10.1371/journal.pgph.0000050*
30. Obeagu EI. Public-private partnerships in tackling sickle cell disease in Uganda: a narrative review. Ann Med Surg (Lond). 2025;87(6):3339-3355. *https://doi.org/10.1097/MS9.0000000000003082*
31. Ally M, Balandya E. Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa. Semin Hematol 2023;60(4):192-199. *https://doi.org/10.1053/j.seminhematol.2023.08.002*
32. Egesa WI, Nakalema G, Waibi WM, *et al*. Sickle cell disease in children and adolescents: A review of the historical, clinical, and public health perspective of Sub-Saharan Africa and Beyond. Int J Pediatr 2022; 2022:3885979. *https://doi.org/10.1155/2022/3885979*
33. Adebamowo SN, Francis V, Tambo E, *et al*. Implementation of genomics research in Africa: Challenges and recommendations. Glob Health Action 2018;11(1):1419033. *https://doi.org/10.1080/16549716.2017.1419033*
34. Ochola R. The case for genomic surveillance in Africa. Trop Med Infect Dis 2025;10(5):129 . *https://doi.org/10.3390/tropicalmed10050129*
35. Misau YA, Al-Sadat N, Gerei AB. Brain-drain and health care delivery in developing countries. J Public Health Afr 2010;1(1): e6. *https://doi.org/10.4081/jphia.e6*
36. Pang T, Lansang MA, Haines A. Brain drain and health professionals. BMJ 2002; 324(7336):499-500. *https://doi.org/10.1136/bmj.324.7336.499*
37. Saleh M, Sharma K, Shamshudin A, *et al*. Regulatory approval of clinical trials: is it time to reinvent the wheel? BMJ Glob Health 2024;9(1): e013727. *https://doi.org/10.1136/bmjgh-2023-013727*
38. Bulgin D, Tanabe P, Jenerette C. Stigma of sickle cell disease: A systematic review. Issues Ment Health Nurs 2018; 39(8):675-686. *https://doi.org/10.1080/01612840.2018.1443530*
39. Grismore C, Roberts LR, Lister ZD, *et al*. Barriers to care for adults with sickle cell disease: A qualitative descriptive study. Health Expect 2025; 28(3): e70310. https://doi.org/10.1111/hex.70310
40. Doble A, Sheridan Z, Razavi A, Wilson A, Okereke E. The role of international support programmes in global health security capacity building: A scoping review. PLOS Glob Public Health 2023;3(4): e0001763. *https://doi.org/10.1371/journal.pgph.0001763*